Establishment of an Academic Tissue Microarray Platform as a Tool for Soft Tissue Sarcoma Research. (15th March 2021)

• Record Type: Journal Article
• Authors: Lee, Che-Jui; Wozniak, Agnieszka; Van Cann, Thomas; Timmermans, Iris; Wellens, Jasmien; Vanleeuw, Ulla; Briaire-de Bruijn, Inge H.; Britschgi, Christian; Bovée, Judith V. M. G.; Zlobec, Inti; Sciot, Raf; Schöffski, Patrick
• Other Names: Verhoef Cornelis Academic Editor.
• Is Part Of: Sarcoma. Volume 2021(2021)
• Publication Date: 2021-03-15
• Subjects: Sarcoma -- Periodicals; 616.994
• DOI: 10.1155/2021/6675260
• Languages: English
• ISSNs: 1357-714X

Abstract

Abstract : Soft tissue sarcoma (STS) is a heterogeneous family of rare mesenchymal tumors, characterized by histopathological and molecular diversity. Tissue microarray (TMA) is a tool that allows performing research in orphan diseases in a more efficient and cost-effective way. TMAs are paraffin blocks consisting of multiple small representative tissue cores from biological samples, for example, from multiple donors, diverse sites of disease, or multiple different diseases. In 2015, we began constructing TMAs using archival tumor material from STS patients. Specimens were well annotated in terms of histopathological diagnosis, treatment, and clinical follow-up of the tissue donors. Each TMA block contains duplicate or triplicate 1.0–1.5 mm tissue cores from representative tumor areas selected by sarcoma pathologists. The construction of TMAs was performed with TMA Grand Master (3DHistech). So far, we have established disease-specific TMAs from 7 STS subtypes: gastrointestinal stromal tumor (72 cases included in the array), alveolar soft part sarcoma ( n = 12 + 47), clear cell sarcoma ( n = 22 + 32), leiomyosarcoma ( n = 55), liposarcoma ( n = 42), inflammatory myofibroblastic tumor ( n = 12 + 21), and alveolar rhabdomyosarcoma ( n = 24). We also constructed a multisarcoma TMA covering a representative number of important histopathological subtypes on arrays for screening purposes, namely, angiosarcoma, dedifferentiated liposarcoma, pleomorphic liposarcoma, and myxoid liposarcoma, leiomyosarcoma, malignant peripheral nerve sheath tumor, myxofibrosarcoma, rhabdomyosarcoma, synovial sarcoma, and undifferentiated pleomorphic sarcoma, with 7–11 individual cases per subtype. We are currently expanding the list of TMAs with additional sarcoma entities, considering the heterogeneity of this family of tumors. Our extensive STS TMA platform is suitable for rapid and cost-effective morphological, immunohistochemical, and molecular characterization of the tumor as well as for the identification of potential novel diagnostic markers and drug targets. It is readily available for collaborative projects with research partners.